Category: Health

  • Cigna, HelloFresh Team Up To Improve Access to Healthy Food

    Cigna, HelloFresh Team Up To Improve Access to Healthy Food

    Cigna Healthcare launched a partnership with HelloFresh on Tuesday to expand access to healthy food for those covered by their employer.

    Bloomfield, Connecticut-based Cigna Healthcare is the health benefits division of The Cigna Group. The insurer has about 19.5 million members. HelloFresh, based in Berlin, Germany, is a healthy food company that delivers food and recipes to people’s homes.

    Through the new partnership, up to 12 million members of Cigna’s employer customers will gain access to HelloFresh’s meals at a discounted rate. Employees can receive e-gift cards, discounted meal kit subscriptions or one-time food box deliveries. Each delivery includes pre-portioned ingredients and steps on how to make the meal. The members can receive these offerings without a HelloFresh subscription.

    “This partnership emphasizes the important role that home cooking plays in supporting consumers’ overall health and well-being,” said Adam Kalikow, senior vice president and managing director of meal kits at HelloFresh U.S., in a statement.

    In addition to supporting Cigna’s members, the insurer and HelloFresh are partnering through HelloFresh’s Meals with Meaning program. The program offers free meal kits to those battling food insecurity in local communities.

    Cigna chose HelloFresh as a partner because it provides “access to fresh food through different food delivery plans and price points and also shares Cigna Healthcare’s commitment to making a difference in our communities,” said Heather Dlugolenski, U.S. commercial strategy officer for Cigna Healthcare, in an email. “By partnering with HelloFresh, we can bring our clients discounted meal kit options to make wholesome eating easy, accessible, and affordable for their employees.”

    There’s a need for more affordable access to healthy food, research shows. According to Cigna’s 2023 Vitality in America study, about one in three U.S. workers reported facing food insecurity within the previous three months. In addition, about six in 10 Americans have at least one chronic disease, according to the CDC. Diet-related chronic diseases represent about 20% of healthcare costs each year in the U.S.

    “We’re seeing a greater push from organizations big and small towards health equity, taking social determinants of health into account, to help ensure all people have the opportunity to achieve optimal health and live with vitality,” Dlugolenski said. “This is playing out in a concerted effort between employers and payers to build equitable and inclusive benefits.”

    In partnering with HelloFresh, Dlugolenski added that Cigna’s goal is to “support the health and vitality of America’s workforce and to make a difference for communities in need.”

    Several other healthcare organizations are also making efforts to tackle food insecurity, though they have different strategies. Elevance Health recently hired a food as medicine director. Alignment Healthcare launched co-branded Medicare Advantage plans with Instacart. Highmark Health has a pilot in West Virginia that offers eligible residents debit cards to purchase healthy food at Dollar General stores. In addition, Kaiser Permanente made a $50 million commitment to food and nutrition security.

    Photo: fcafotodigital, Getty Images

  • Why Communicating Data Results is Critical to Long-Term BioPharma Success

    Why Communicating Data Results is Critical to Long-Term BioPharma Success

    Early-stage biotech companies experience many important inflection points from funding milestones to regulatory updates to an IPO. However, data readouts arguably carry the biggest risks and potential rewards. Whether providing proof of concept, proving safety and tolerability, or clearing the way for final regulatory approval, clinical trial readouts are critical de-risking events. Communicating a clear, consistent message to your audiences is crucial to success, no matter what the data show.

    Preparation for a data event should begin long before the data are in hand. In fact, the most sophisticated and equipped companies are the ones that begin preparing for the trial’s completion when only just beginning to conceptualize their clinical development program.

    Stakeholder analysis

    Communicating early and often with investors, analysts, the scientific community, and other key audiences is fundamental to long-term success. As you are determining your biomarkers, endpoints, and other details, ensure your communities understand the goals of your clinical development program and the milestones that are anticipated along the way. Providing a clear and unwavering roadmap of anticipated milestones will ensure that, no matter the inevitable bumps or detours, your stakeholders can always see the path forward and track your progress.

    One of the first exercises management teams should undertake when considering their clinical development path is a stakeholder analysis. Investors, analysts, patients, potential partners, prospective employees – each audience has their own concerns and expectations. Understanding the interests and apprehensions of your community is key to developing messaging that not only resonates, but reassures your key audiences.

    While best practice is always to tailor your messaging to the needs of your specific audience, it is important to remember that in our digital age, messages are both immutable and porous. Milestones communicated early in your development are forever searchable and even private companies will have to answer for missed timelines when they have been recorded for posterity.

    Additionally, with social media, video sharing services, and global search, information created for one audience is often shared amongst many. Evaluate all materials and messages developed through the unique lens of each of your audiences. What would you change about your scientific presentation if it was recorded and accessible to your patient and caregiver community on YouTube after the event? What is in your quarterly earnings updates that might concern your KOLs or clinical investigators? Evaluating the impact of messages on each of your audiences in addition to your intended targets is essential.

    The importance of feedback loops

    Listening is a vital element of any successful communication program and one that is frequently overlooked. In a global survey by the Economist Intelligent Unit (EIU), which surveyed 500 companies, 63% of companies said feedback loops help them to implement new strategies based on updated information to reach strategic goals. Too often, companies treat conversations with their core audiences as one-way interactions, but the most strategic and forward-thinking leadership teams use these early interactions as important sources of insight. After each conversation, take a moment to reflect. What questions surprised you from investors? What concerns are patients or caregivers raising that you haven’t addressed? Was there a concept the scientific community didn’t seem to grasp? Fill the gaps in your messaging early and update accordingly as your work progresses.

    Timing is critical 

    Once the first participant has been dosed and the trial is progressing as planned, companies should quickly shift into preparing to receive and disseminate the data. No less than 90 days before the interim or final read, management teams should start to forecast potential outcomes and prepare accordingly.

    Working in close collaboration with patient advocacy, legal, clinical, regulatory, IR, PR, and other key stakeholders, leaders should plan for positive, negative, and neutral outcomes. Every possible outcome should be evaluated through the lens of each audience and their concerns and expectations. What are the variables that will need to change with the different scenarios? What are the regulatory implications of the findings – will you be seeking accelerated approval, for example? Will you communicate the nuances around each scenario? How will analysts, investors, and patients view the results?

    Addressing the laundry list of questions and considerations is only the first step in scenario planning. For each foreseeable outcome, companies must develop supporting materials including Q&As, press releases, decks, scripts, etc. that are vetted and approved by legal, regulatory, and management. Tackling these all-important elements early will help the team to unearth and address misalignment and ensures that when the data are available, everyone agrees on the approach and next steps.

    Once the data are in hand, the materials are finalized, and the messages have been shared with external audiences, management teams should evaluate the success of the event and begin planning for the next stage. What resonated and what fell flat? What points were particularly confusing for patients? What signals did analysts give about their expectations for upcoming milestones? How can you begin preparing and adapting your message today for future milestones?

    With so many potential hurdles on the road to commercialization, it’s important to be proactive and have a solid plan to address the elements within your control – you can’t control the data, but a robust plan will ensure you are prepared for all possible results.

    Source: exdez, getty images

  • Firefly Bio Unveils M to Illuminate the Startup’s New Take on ADC Cancer Meds

    Firefly Bio Unveils $94M to Illuminate the Startup’s New Take on ADC Cancer Meds

    The class of cancer therapies known as antibody drug conjugates showed toxic drug payloads can be delivered to tumors in a targeted way. The first ADCs delivered chemotherapy, but the field is also testing other payloads. Firefly Bio, a Versant Ventures-backed startup, is now out of stealth with $94 million, joining a growing cohort of companies working to expand the ADC field.

    An ADC is modular, comprised of a targeting antibody and a drug payload that are hitched together by a chemical linker. The ADCs currently available and many more that are in development employ chemo as the drug payload. South San Francisco-based Firefly is offering an ADC with a twist. Its therapies carry drug payloads that work by degrading a disease-causing protein. This new types of ADC is called a degrader antibody conjugate, or DAC.

    Firefly aims to overcome some of the limitations of traditional ADCs. The powerful cancer-killing ability of an ADC’s chemo drug payload means the therapy has a limited therapeutic index, the dose range that balances safety and efficacy, the company said. Also, ADCs lack the ability to address specific proteins within a cell. Meanwhile, protein degraders can selectively address protein targets within a cell, eliminating them. But Firefly notes that one limitation of degraders is their bioavailability, or how much of a drug is available in the body’s circulation to offer a therapeutic effect. Degraders also do not have the ability for cell-specific targeting.

    By combining an ADC with a degrader overcomes, Firefly aims to overcome the limitations of each modality. The startup employs a proprietary linker technology called Firelink that it says decreases how much of the drug payload goes into the circulation, where it can be picked up by healthy tissue. Consequently, a Firefly therapy requires a lower dose to achieve optimal efficacy. According to the company, preclinical research in both solid and liquid tumors showed a single administration of a Firefly DAC led to “significant reductions in tumor volume at very low doses.”

    “DACs are a new modality for cancer,” Firefly CEO Scott Hirsch said in a prepared statement. “They give us the ability to hit biologically validated targets with minimal collateral damage. Our platform enables DACs at scale and vastly expands the number of payloads for ADCs.”

    In a report issued earlier this month, Leerink Partners analyst Christopher Liu said that despite the targeting ability of the antibody component of an ADC, these drugs are known for toxicities. DACs could be safer than ADCs while still being efficacious. He added that this emerging class of drugs is drawing interest from some larger pharma companies, which see them as a way to expand beyond traditional ADCs.

    Last September, protein degrader developer Nurix Therapeutics struck up a research alliance with ADC-specialist Seagen, now a part of Pfizer. The targets of the collaboration were not disclosed. Last November, Bristol Myers Squibb paid $100 million up front to acquire an Orum Therapeutics DAC candidate ready for Phase 1 testing in blood cancers. In December, Merck entered DAC R&D through an alliance with C4 Therapeutics. The cancer target of this alliance remains undisclosed. The companies said the pact could expand to additional targets.

    Firefly’s Series A round was co-led by Versant and MPM BioImpact. Decheng Capital and Eli Lilly also joined the financing. Firefly has not disclosed the targets of its research. In the financing announcement, Jeral Davis, managing director at Versant and a Firefly board member, said the startup is discovering DACs for use in oncology and immunology.

    Firefly was incubated at Ridgeline Discovery Engine, Versant’s startup creation entity in Switzerland. There the company said it established proof-of-concept for its lead asset. Firefly has not offered any timelines for reaching clinical testing with this asset.

    Image: Getty Images

  • Celebrating Black History and Advancing Health Equity for Safer Patient Care | Blogs

    Celebrating Black History and Advancing Health Equity for Safer Patient Care | Blogs

    Celebrating Black History and Advancing Health Equity for Safer Patient Care | Blogs
    Dr. TaRessa Wills

     

    February is Black History Month, a time to reflect on the contributions and experiences of African Americans throughout United States history. This year, CDC’s Project Firstline had the privilege of speaking with Dr. TaRessa Wills, a Black female physician, about what the observance means to her and the importance of advancing health equity to make health care safer for all.

    Black Americans’ Contributions to Health Care are an Important Part of American History

    To start the conversation, Dr. Wills emphasized the uniqueness of the African American story and how it has shaped our shared national identity. It’s important to recognize and remember those who dedicated their lives to bring us together, like Dr. Martin Luther King Jr., whose fight for justice laid the groundwork for greater access to racial and health equity. However, she noted there are still many overlooked figures and narratives that need to be elevated.

    Dr. Wills highlighted the contributions of pioneering Black doctors like Rebecca Lee Crumpler and James McCune Smith, the first Black female and male physicians in the U.S., as sources of inspiration for her own career.

    Representation Matters

    Dr. Wills noted the growing body of evidence to support that Black patients often have better outcomes when treated by Black providers – which she has seen personally in her work. [1] Structural and institutional racism are common obstacles to ensuring equitable care for all patients. One recommendation to help address health disparities is through growing a more diverse provider workforce that better represents the patient populations in their communities. As a member of the Black community, Dr. Wills can more easily identify and connect with her patients while sharing scientifically accurate information and modeling positive healthcare interactions.

    Dr. Wills spoke passionately about her role as an advocate who takes time to understand patients’ lived experiences and rectify false assumptions in their medical charts so they can receive the best care possible. “There’s all of this language in a medical chart that speaks to a more negative tone of what’s going on with this individual patient who identifies as black, which can carry forth and perpetuate falsehood about them, which can go into how that patient’s treated.” For example, a patient’s chart could note they are chronically late for appointments, not following through with their home care plan, or not taking their medications as prescribed. But having an unbiased conversation with the patient may illuminate barriers preventing them from following through on their care, such as transportation issues, cost of medications, or even language or cultural differences.

    With an understanding of a patient’s specific situation, providers can then work with their patients to create a more customized approach that will hopefully keep them safe from infections and lead to better long-term outcomes. She stressed the importance of building trust with her patients, meeting them where are they are, and connecting with them through shared cultural experiences and faith-based thinking.

    Prioritizing Infection Prevention and Control

    When you consider other factors that contribute to positive healthcare interactions, infection control is also a critical part of building trust in safer care and improving patient outcomes. We asked Dr. Wills to share how infection control impacts her approach to patient care.

    She commented that sometimes marginalized communities, especially black and undocumented peoples who are uninsured, will need quicker solutions or emergency treatment to address chronic health issues.  For example, an uninsured person needing dialysis may go to the emergency room for treatment, as opposed to someone who is an established patient at a facility receiving a care plan with regularly scheduled appointments and treatment. “People aren’t taking time to talk to them and educate them about their options.” The variability in care patients receive and the time spent waiting in the emergency room creates a possibility of excess risk for infection or illness.

    She also mentioned, “If you’re talking about the spread of respiratory diseases, there are increased infection risks when [patients] come in – and there is risk of them [patients] going back to their communities and spreading it around.” CDC provides recommendations and resources on how healthcare providers can implement infection control measures within their facilities to help stop the spread of germs and protect patients and others from infections. Relevant infection control measures may include hand hygiene, masking for source control, screening and triaging, use of personal protective equipment, and cleaning and disinfection, among others. It’s also important to talk to patients and educate them about what they can do once they leave the facility to limit spread of potential infections.

    Dr. Wills underscored the importance of recognizing these inherent challenges within the system and working to overcome the gaps to provide inclusive care for all patients.

    Achieving Health Equity

    To advance health equity, we must identify and reduce the barriers to safe patient care for black patients and educate staff on culturally appropriate solutions. In her approach, Dr. Wills noted that she sees every patient as having the opportunity to improve their health and wellbeing regardless of what they look like or their previous experiences. She guides patients to make lifestyle changes and treatment choices that will improve their health on their own terms. Her empathy and cultural dexterity play a crucial role in her ability to connect with patients on a deep, emotional level for personalized care. This enables Dr. Wills to better assess her patient’s needs and tailor her care accordingly.

    Kindness Always Wins

    Overall, Dr. Wills’ message is one of kindness – to healthcare providers and most importantly their patients. While change is still needed, individual acts of understanding and compassion can make a real difference. “…I absolutely love what I do. I love the ability to help endorse wellness. I have the ability to help people know that they are loved. We care about you…I love being a part of that journey. I love being a part of their individual discoveries of health care and wellness.”

    As we recognize Black History Month, Dr. Wills’ words are a stirring reminder that health care is about serving human beings in all their complexity. This principle is especially pertinent as it relates to healthcare equity, personalized care, and infection control. In celebrating black leaders like Dr. Wills, we are inspired by the commitment to these principles. Though the work is far from finished, Project Firstline is committed to elevating the stories of those on the frontlines and providing the education and training needed to make health care safer for all.

    [1] Peek ME. Increasing Representation of Black Primary Care Physicians—A Critical Strategy to Advance Racial Health Equity. JAMA Netw Open. 2023;6(4):e236678. doi:10.1001/jamanetworkopen.2023.6678

     

    Biography:

    Dr. TaRessa Wills earned her Bachelor of Science degree in Biomedical Engineering from the Georgia Institute of Technology in Atlanta, GA followed by her Doctorate of Medicine from Howard University College of Medicine in Washington, DC. She completed her Internal Medicine residency in the United States Army at Walter Reed National Military Medical Center in Bethesda, MD. She transitioned her military career from the United States Army as a Major to solely civilian medicine in 2017. Dr. Wills is currently a board-certified Internal Medicine physician who joined Emory University School of Medicine faculty as an Assistant Professor of Medicine in the Emory Division of Hospital Medicine at Grady Memorial Hospital in 2019.  Clinically, she fervently delivers compassionate, direct care to Atlanta’s most vulnerable populations and strives to educate internal medicine residents, medical students and physician assistant students on how to integrate cultural competence and empathetic kindness in patient care. She holds interests in diversity, equity, inclusion and racial advocacy and enjoys reading and spending time with family and friends. Dr. Wills extends her service to the community as a proud member of Alpha Kappa Alpha Sorority, Incorporated.

     

    Authors:

    Mia Frederick (contractor, TANAQ) is a writer for CDC’s Project Firstline in the Division of Healthcare Quality Promotion.

    Brittney Foster (contractor, St. John’s Group/Tanaq) is a senior health communications specialist for CDC’s Project Firstline in the Division of Healthcare Quality Promotion.

  • Are You a Healthcare Startup Looking for Investors? Sign Up for MedCity’s Pitch Perfect Contest!

    Are You a Healthcare Startup Looking for Investors? Sign Up for MedCity’s Pitch Perfect Contest!

    Large group of business people preparing for a race on a starting line in the office. Copy space.

    Are you a healthcare startup in health tech, diagnostics, medtech, or biotech? If so, you should consider applying to the MedCity News startup pitch contest at the INVEST conference at the Ritz Carlton in Chicago, May 21-22. The deadline to submit applications is February 29.

    The Pitch Perfect contest has four tracks geared to a specialty in each category:

    Biopharma
    Startups focused on oncology

    Devices & Diagnostics 

    Startups focused on cardiology

    Healthtech: Consumer/Employer
    Startups addressing women’s health

    Healthtech: Payer/Provider
    Startups addressing burnout and operational efficiency

    Six finalists will be selected for each track and will have the opportunity to present to an audience of investors. The investor judges in each track will hear each pitch and ask questions of each presenter before selecting a winner.

    There is no fee to apply. Startups that have been a finalist and pitched at any INVEST event in the past 12 months are not eligible to apply. Startups should apply to only one track. Startups must be registered for the conference in order to participate in the pitch contest. The startup rate is $695 and a code will be sent to those selected to pitch.

    Investment professionals will review applications and selections will be announced starting March 31, 2024.

    Disclaimer: Each Pitch Track winner will receive a $20,000 advertising credit to be used on MedCityNews.com. The advertising opportunities that are available to select from include: display advertising, sponsored post, sponsored text ad, dedicated and targeted email blast, executive interview, and video spotlight. A MedCity News media kit will be provided to each winner to reference the rate for each opportunity included above. Advertising credit must be used by May 21, 2024, cannot exceed $20,000 in value, and may not be combined with any other offers or discounts.

    To submit an application, click here.

    Photo: skynesher, Getty Images

  • Healthcare worker shortage: How to fill the gaps

    Healthcare worker shortage: How to fill the gaps

    Categories


    Archives


  • Despite Price Transparency Laws, Americans Are Nowhere Near Able to Shop for Care. How Can This Change?

    Despite Price Transparency Laws, Americans Are Nowhere Near Able to Shop for Care. How Can This Change?

    Despite Price Transparency Laws, Americans Are Nowhere Near Able to Shop for Care. How Can This Change?

    Less than one-fifth of U.S. adults know the cost of their healthcare products and services prior to receiving them, according to the results of a new Gallup poll. The results were released this month — more than three years after CMS began enforcing its price transparency rule for hospitals, and more than a year after payers were also required to publicly disclose their rates. 

    CMS said that the goal behind its price transparency legislation is to help patients become aware of their care options, understand the associated costs and potentially drive down overall healthcare costs through increased competition and educated consumer choices.

    Becaause of this legislation, healthcare pricing data is now available — but that doesn’t mean it makes any kind of sense to the average American given the way it’s presented to them on payer and provider websites. One might argue that the legislation was first about shedding light on the very opaqueness of the industry. Now that has been achieved to a degree, and the ball is in the court of healthcare software companies who need to create easy-to-use, personalized tools.  

    What has happened since the legislation took effect?

    Price transparency experts agree that we’re still a long way away from living in a world where consumers can easily plug some information into a Kayak.com-style tool and receive an instant, accurate price estimation for their healthcare. However, they do think the industry has taken the first step toward a future like that.

    “The data coming out was a big first step. The data improving and continuing to improve is another important building block,” said Marcus Dorstel, vice president of operations at Turquoise Health, a price transparency software startup.

    He also pointed out that both hospitals and payers have reached widespread compliance with CMS’ price transparency requirements. This wasn’t always the case — especially among hospitals, which initially struggled greatly to publish the highly complex billing data. 

    Part of the reason hospitals and payers have improved has to do with the fact that CMS became stricter about issuing fines for price transparency noncompliance last year, he noted. Another part of it stems from hospitals’ desire to represent themselves accurately to the public, Dorstel pointed out.

    “We’ve seen that organizations within the U.S. healthcare system are actually using this data and accessing these files to make business decisions and negotiate new contracts. So you need to make sure you have accurate and usable information and that you’re being represented to other organizations in the right way,” he declared.

    Unpacking the intent of the legislation

    While consumer awareness about CMS’ price transparency rules is not where it needs to be, it too seems to be improving, not unlike how compliance from providers has gotten better.

    Dorstel’s employer’s site — which compiles, cleans and displays the pricing data that hospitals and payers publish — had about 10,000 monthly users around the time CMS’ hospital price transparency rule went into effect, but now that figure is close to 50,000 or 60,000, he said.

    But when you think about how many people receive care under our country’s healthcare system, that figure isn’t very big at all. It remains true that most Americans are unaware that providers and payers are required to post their prices, but that doesn’t mean that CMS’ price transparency regulations have failed, Dorstel pointed out.

    In his view, price transparency regulations seek to do more than help consumers shop for care. When CMS began requiring hospitals and payers to post their cost data, the agency was trying to bring shadowy prices into the light for the whole industry, he noted.

    “The intent of the legislation was for companies — software companies, health tech companies, as well other entities in healthcare — to use that data to inform better decision making and bring economic forces into play. Before, the price of healthcare was unknown, and so there could be no economic forces influencing those prices. Now with prices being transparent and out there, you have more and more organizations making business decisions based off of that data,” Dorstel explained.

    To him, price transparency legislation seeks not only to help consumers save money, but also to lower overall healthcare costs. If payers and other businesses chose not to partner with a provider whose prices are higher than its competitors on the market, then that provider could very well be forced to lower their prices — over time, the increased instance of these types of scenarios could lead to lower costs across the healthcare delivery ecosystem, Dorstel remarked.

    Amanda Eisel — CEO of Zelis, a healthcare payment technology company — agreed with Dorstel that CMS’ vision for the future of price transparency legislation was never a situation in which consumers visit a hospital website, download a mammoth file, and then scroll down to Row 3,986 to locate the price of a procedure they are undergoing. CMS’ intention was to get pricing data out in the open so that technology companies could step in and get to work on cleaning that messy data and building tools to help consumers understand it, she declared. 

    “The government said ‘We know this data in its raw form is just inherently not useful. You can’t understand it. We’re trying to free the data so that entrepreneurial companies can figure out how to use it so that consumers actually can have that price transparency,’” Eisel said.

    It will probably take another five to 10 years until healthcare pricing data actually becomes useful for the American public, she added.

    What the future could look like

    Creating state-of-the-art software to process high complex data in a consumer-friendly way isn’t a task that hospitals or providers are well-equipped to handle. On the price transparency journey, the main role of these two groups is to make their data transparent and available — not understandable. As we embark on the next phase of the journey, it looks like software vendors and other tech companies will need to do some heavy lifting, Eisel predicted.

    In order to build tools that consumers can eventually interact with regularly, there are a few key steps that health tech vendors can begin taking, she noted. For starters, she said that health tech companies need to start grouping pricing data for billing codes that are commonly used together in episodes of care.

    “Part of the challenge with this raw data is that when you go in for any sort of procedure, you’re likely not going in just for one CPT code — but that is how the data is released. You’re going in for an episode of care, so that requires looking at the historic data and showing that when someone goes in for this, it actually results in these 15 codes that have to be grouped together, and that based on a high probability, this is going to be the cost of care,” Eisel explained.

    For example, a person who needs a hip replacement may look at the CPT code for their arthroplasty and think they have suitable price estimation. But in reality, they need to be looking at a variety of different codes for services that are bound to be delivered during the episode of care, such as preoperative evaluation, anesthesia administration, wound care, physical therapy, medication, imaging and lab tests.

    Healthcare software developers should also be aware of the importance of personalization, Eisel pointed out. 

    “When you think about it, what does a consumer care about? What they really care about is the price transparency data in the context of their health insurance. This isn’t like any other industry where a price is a price. In healthcare, you have to think about deductibles, copays and which providers are in-network and out of network for the price to be relevant,” she explained.

    Future price transparency tools need to consider all those factors before they can be truly useful for consumers, Eisel declared.

    Another price transparency expert — Hal Andrews, CEO of healthcare analytics company Trilliant Health — pointed out that the billing codes used in healthcare are a foreign language to most Americans. With these codes at the center of the pricing data released by hospitals and payers, tech companies need to use generative AI to help translate those codes and other medical pricing jargon in easily digestible terms, he declared.

    “Maybe the best use for ChatGPT in healthcare is to translate Medicalese into English,” Andrews remarked.

    How employers can help

    Should health tech vendors create easy-to-use price transparency tools for consumers in the next few years, that still wouldn’t be enough to get Americans to use pricing data to shop for their care, Eisel of Zelis argued. In her view, the healthcare industry needs to dedicate more effort to increasing Americans’ awareness of price transparency initiatives and trust in publicly available pricing data.

    Employers are going to have to get more involved in increasing this awareness and trust, Eisel declared. 

    Andrews also believes employers should take on a bigger role when it comes to increasing consumers’ interaction with price transparency data, as this data is most useful to the commercially insured population.

    “I think the only place where you can really have consistent utility is when the employer makes it easy for the employees to see the information, to understand the information and to make better choices based on the information,” he explained.

    To him, it’s naive to assume consumers will voluntarily search for their healthcare prices. However, Andrews thinks people may search if encouraged by their employer. Some actions employers can begin to take include deploying emails letting employees know what tools are available to them, providing employees with resources that help translate medical jargon, and offering workshops on how to navigate pricing data and estimator tools, he explained.

    Like Eisel and Dorstel, Andrews thinks price transparency data will remain mostly useless for consumers for at least another five years. But now that the groundwork has been laid, healthcare software companies have their work cut out for them.

    Photo: AlisLuch, Getty Images

  • Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting

    Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting

    Omada, a virtual healthcare provider, announced Tuesday that it is expanding its GLP-1 companion solution to include musculoskeletal exercise programming and member-level reporting for employers, payers and pharmacy benefit managers.

    San Francisco-based Omada serves employers, health plans and health systems and provides virtual care for diabetes, weight management, hypertension, musculoskeletal issues and behavioral health. It launched its GLP-1 program last year to offer lifestyle and behavior support to patients struggling with chronic obesity and taking GLP-1s, but is not prescribing GLP-1s itself. The core GLP-1 program offers side effect support, nutrition guidance, online support communities and weight loss and maintenance resources.

    The newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. This kind of support is needed because muscle health is vital to maintaining weight loss, according to Wei-Li Shao, president at Omada Health.

    “The important thing here is that if somebody decides to go off a GLP-1, they need muscle health support in order to sustain the outcomes that they’ve experienced,” Shao said in an interview. “If you gain all the weight back, the return on investment dissipates.”

    In addition to the musculoskeletal exercise support, Omada is offering enhanced reporting and insights for employers, payers and PBMs on the members participating in the company’s GLP-1 program. This reporting will help them understand who is responding to GLP-1s and who is not, as well as who is engaging with the program. 

    “We can see whether or not they are adherent to their medications,” Shao said. “Are they complying? Are they getting their refills? Do they have challenges getting the medications and getting their refills? How are they experiencing side effects and do they need additional support there? The worst case scenario would be for somebody to actually stop their GLP-1 but need it just because they didn’t have the right support.”

    Omada’s expanded program comes at a time when it’s estimated that the GLP-1 market could exceed $100 billion by 2030. When taking GLP-1s, people with obesity can lose up to 15% of their body weight, but risk gaining the weight back if they don’t follow the proper protocols.

    Shao added that the popularity of GLP-1s is part of a larger trend in healthcare that combines medicine with behavior change.

    “There is an intersection between biology and behavior,” he said. “What that means is that something biologically needs to be treated, for instance, by medication or some other care intervention. But how you run your life, the decisions you make, your behavior are equally important. That intersection between the two, we believe, is a trend in healthcare that is being accelerated by the conversation with GLP-1s in the necessity to have a lifestyle behavior change intervention program as a companion alongside.”

    Omada isn’t the only company supporting patients taking GLP-1s. Other companies include WeightWatchers, Noom, LifeMD and Found. However, Omada differs because it isn’t actually prescribing GLP-1s like these other companies are.

    In expanding its GLP-1 program, Omada’s ultimate goal can be summarized in one word: sustainability, Shao said.

    “We’re focused on the long-term journey and sustainability of the benefit of GLP-1s and how they can be optimized, amplified and sustained over a period of time,” he said.

    Photo: Peter Dazeley, Getty Images

  • Episode 1: Debunked (audio): Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare

    Episode 1: Debunked (audio): Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare

    In the first episode of Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare, co-hosts Arundhati Parmar and Samir Batra discuss bad billing practices related to Arundhati’s foot fracture while Samir offers solutions to the problem. They also discuss the annual J.P. Morgan Healthcare Conference, drug pricing and a healthcare transaction between General Catalyst and Summa Health.

    Here’s the audio:

    The video is available on YouTube.

  • FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolves

    FDA Approves New First-Line Med for Pancreatic Cancer as Drug’s Initial Developer Dissolves

    Pancreatic cancer continues to be one of the most difficult-to-treat cancers. An Ipsen drug is now approved as a first-line therapy, moving it up in the treatment hierarchy for this type of cancer.

    The drug, Onivyde, was initially approved as a second-line therapy for pancreatic cancer in adults whose disease has advanced following treatment with standard chemotherapies. In expanding to first-line treatment of metastatic disease, the drug must continue to be used in combination with chemotherapy, according to the FDA announcement Tuesday. The approval covers use of the infused therapy for the treatment of pancreatic adenocarcinoma, or PDAC, the most common type of pancreatic cancer.

    The cancer-killing agent in Onivyde is a widely used chemotherapy called irinotecan. This drug works by blocking topoisomerase I, an enzyme key to cancer cell replication. The innovation of Onivyde is the enclosure of irinotecan in tiny fat particles called liposomes. These particles are intended to reduce the leakage of the drug payload before the therapy reaches the tumor. Accumulating at the tumor site, the liposomes release the drug slowly over time, according to Paris-based Ipsen.

    The liposome technology used in Onivyde is from Cambridge, Massachusetts-based Merrimack Pharmaceuticals, which initially developed the drug and steered it to a 2015 FDA approval. In 2017, Ipsen paid $575 million up front to acquire Onivyde and another Merrimack cancer drug. Ipsen ran the Phase 3 studies testing Onivyde as a first-line pancreatic cancer therapy.

    The pivotal clinical trial enrolled 770 patients with metastatic pancreatic cancer. These patients had not previously received chemotherapy to treat their metastasized disease. Participants in the study drug arm received Onivyde and three standard of care drugs, including two chemotherapies, a combination typically shortened to NALIRIFOX. Onivyde is administered as a 90-minute intravenous infusion. In the study, the Ipsen drug was administered first followed by the other rest of the NALIRIFOX drugs in succession. The control arm was treated with two standard-of-care chemotherapies, gemcitabine and nab-paclitaxel.

    The clinical trial’s main efficacy goal was measuring overall survival. Results showed the study drug arm achieved median overall survival of 11.1 months compared with a median 9.2 months in the chemotherapy arm, which was enough to be statistically significant. Median progression-free survival was 7.4 months for NALIRIFOX and 5.6 months in the chemotherapy arm. The most common adverse reactions reported in the study included diarrhea, fatigue, nausea, vomiting, and abdominal pain. The drug’s label continues to carry a black box warning for risks such as severe diarrhea and severe neutropenia, which is a low number of neutrophils, a type of white blood cell.

    “With today’s approval, this Onivyde (NALIRIFOX) regimen can now offer a potential new standard-of-care treatment option with proven survival benefits for people living with metastatic pancreatic adenocarcinoma in the U.S.,” Christelle Huguet, executive vice president and head of research and development, Ipsen, said in a prepared statement.

    Ipsen holds U.S. rights to Onivyde and reported €162.4 million in sales for the drug in 2022, a 27.4% increase over sales in the prior year. Servier, which holds the drug’s rights outside of the U.S. and Taiwan, launched the product in 2020. The company reported €145 million in Onivyde sales for the financial year ended Sept. 30, 2022, up 13.7% compared to the prior financial year.

    Ipsen’s acquisition of Onivyde put Merrimack in line for up to $450 million in milestone payments. Approval of the drug as a first-line pancreatic cancer treatment triggers a $225 million milestone payment. The deal also calls for a $150 million milestone payment if Onivyde is approved in small cell lung cancer and $75 million for an additional approval in another indication other than lung or pancreatic cancers.

    Merrimack no longer has any R&D, or anything else for that matter. A 2019 restructuring cut all of its employees, including management. The company exists solely to “preserve our ability to capture the potential milestone payments resulting from the Ipsen sale,” it said in its 2023 annual report. Following Onivyde’s approval as a first-line treatment for pancreatic cancer, Merrimack announced that its board of directors has concluded it is unlikely any additional milestone payments will become payable.

    Merrimack is now planning a May meeting during which stockholders will vote to approve a plan to dissolve the company. Merrimack shareholders won’t be left emptyhanded. The plan of dissolution includes a liquidating dividend expected to pay out between $14.65 and $15.35 per share, which is contingent on the receipt of the Ipsen milestone payment. The plan also includes the establishment of a liquidating trust to disburse any future milestone payments that Merrimack might receive.

    Public domain image by the National Cancer Institute